Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Biotech Histochem ; 92(7): 467-480, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28836856

RESUMO

Amiodarone (AM) is an effective anti-arrhythmic drug. We investigated the role of mast cells and macrophages on AM induced pulmonary fibrosis and the action of atorvastatin on this fibrosis. Rats were allocated into four groups; negative control (1), positive control (2), 30 mg/kg body weight/day AM (3) and AM + 10 mg/kg/day atorvastatin (4). Lungs were harvested and prepared for histology and immunohistochemistry. Hematoxylin and eosin stained sections of group 3 exhibited disorganized lung architecture. We found cellular debris in the lumen of both intrapulmonary bronchi and bronchioles with partial disruption of the thickened epithelial lining and mononuclear cellular infiltration into the lamina propria. We also observed thickening of the epithelial lining and the smooth muscle layer. Congested, dilated and thickened blood capillaries and thickened inter-alveolar septa were observed with mononuclear cellular infiltrates in the lung of group 3. Most alveoli were collapsed, but some dilated ones were detected. In some alveoli, type ІІ pneumocytes were increased, while type I cells were decreased. We observed significant increases in the amount of collagen in the thickened inter-alveolar septa, around bronchioles and around blood capillaries in sections from group 3. We found a significant increase in mast cells and alveolar macrophages in group 3 compared to group 1. Mast cells and macrophages appear to play important roles in AM induced pulmonary fibrosis. Atorvastatin appears to attenuate this condition.


Assuntos
Amiodarona/toxicidade , Atorvastatina/uso terapêutico , Macrófagos/citologia , Mastócitos/citologia , Fibrose Pulmonar , Animais , Imuno-Histoquímica , Macrófagos/fisiologia , Masculino , Mastócitos/fisiologia , Fibrose Pulmonar/induzido quimicamente , Ratos , Padrões de Referência , Coloração e Rotulagem
2.
Biotech Histochem ; 91(6): 401-11, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27149563

RESUMO

Retinopathy of prematurity (ROP) is a vasoproliferative disorder that occurs in premature infants and may lead to permanent visual impairment. We investigated both the possible protective role of N-acetyl cysteine (NAC) for preventing ROP and the role of IGF-1 in the disorder. Forty-five newborn rats were divided into three groups. Group 1 was raised in room air as controls. Group 2 was exposed to 60% oxygen for 14 days after birth, then transferred to room air. Group 3 was exposed to the same conditions as group 2, but received intraperitoneal injections of NAC on postnatal days 7-17. After 35 days, both eyes of all rats were processed for histology. Some sections were stained with hematoxylin and eosin to assess structural changes and other sections were immunostained to determine the location of IGF-1. Frozen sections also were prepared and stained for adenosine triphosphatase to detect retinal blood vessels. Compared to the controls, more blood vessels, many of which were abnormal, and increased IGF-1 expression were observed in group 2. In group 3, abnormal blood vessels and IGF-1 expression were less evident. NAC appeared to be an effective vascular-protective agent for ROP by decreasing IGF-1 expression.


Assuntos
Acetilcisteína/farmacologia , Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos , Fator de Crescimento Insulin-Like I/genética , Epitélio Pigmentado da Retina/efeitos dos fármacos , Retinopatia da Prematuridade/fisiopatologia , Acetilcisteína/uso terapêutico , Animais , Animais Recém-Nascidos , Linhagem Celular Tumoral , Modelos Animais de Doenças , Sequestradores de Radicais Livres/farmacologia , Sequestradores de Radicais Livres/uso terapêutico , Imuno-Histoquímica , Fator de Crescimento Insulin-Like I/metabolismo , Ratos , Epitélio Pigmentado da Retina/química , Epitélio Pigmentado da Retina/patologia , Vasos Retinianos/efeitos dos fármacos , Retinopatia da Prematuridade/tratamento farmacológico , Retinopatia da Prematuridade/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA